Better glycaemic control and weight loss with the novel long-acting PEGylated basal insulin LY2605541 compared with insulin glargine in patients with type 1 diabetes

被引：0

作者：

Blevins, T. ^{[1
]}

Rosenstock, J. ^{[2
]}

Bergenstal, R. M. ^{[3
]}

Morrow, L. A.

Prince, M. J. ^{[4
]}

Qu, Y. ^{[4
]}

Sinha, V. P. ^{[4
]}

Howey, D. C. ^{[4
]}

Jacober, S. J. ^{[4
]}

机构：

[1] Texas Diabet & Endocrinol, Austin, TX USA

[2] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA

[3] Int Diabet Ctr Pk Nicollet, Minneapolis, MN USA

[4] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

DIABETOLOGIA | 2012年 / 55卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

916

引用

页码：S377 / S377

页数：1

共 50 条

[1] Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Patients With Type 1 Diabetes
Rosenstock, Julio
Bergenstal, Richard M.
Blevins, Thomas
Morrow, Linda A.
Prince, Melvin J.
Qu, Yongming
Sinha, Vikram P.
Howey, D. C.
Jacober, Scott J.
DIABETES, 2012, 61 : A263 - A263
[2] Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes A randomized, crossover study
Rosenstock, Julio
Bergenstal, Richard M.
Blevins, Thomas C.
Morrow, Linda A.
Prince, Melvin J.
Qu, Yongming
Sinha, Vikram P.
Howey, Daniel C.
Jacober, Scott J.
DIABETES CARE, 2013, 36 (03) : 522 - 528
[3] Reduced Nocturnal Hypoglycemia and Weight Loss With Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Patients With Type 2 Diabetes
Bergenstal, Richard M.
Rosenstock, Julio
Arakaki, Richard F.
Prince, Melvin J.
Qu, Yongming
Sinha, Vikram P.
Howey, Daniel C.
Jacober, Scott J.
DIABETES, 2012, 61 : A90 - A91
[4] Weight loss and lower nocturnal hypoglycaemia with novel long-acting basal insulin LY2605541 versus insulin glargine in patients with type 2 diabetes
Bergenstal, R. M.
Rosenstock, J.
Arakaki, R. F.
Prince, M. J.
Qu, Y.
Sinha, V. P.
Howey, D. C.
Jacober, S. J.
DIABETOLOGIA, 2012, 55 : S377 - S377
[5] Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in type 1 diabetes and type 2 diabetes
Jacober, S. J.
Rosenstock, J.
Bergenstal, R. M.
Prince, M. J.
Qu, Y.
Beals, J. M.
DIABETOLOGIA, 2012, 55 : S377 - S377
[6] Novel long-acting basal insulin analogue LY2605541 significantly reduces nocturnal hypoglycaemia and fear of hypoglycaemia compared to insulin glargine in patients with type 2 diabetes mellitus
Curtis, B.
Shi, C.
DIABETOLOGIA, 2012, 55 : S392 - S392
[7] Improved Glycemic Control Despite Reductions in Bolus Insulin Doses With Basal Insulin LY2605541 Compared With Basal Insulin Glargine in Patients With Type 1 Diabetes
Rosenstock, Julio
Bergenstal, Richard M.
Blevins, Thomas
Morrow, Linda
Qu, Yongming
Jacober, Scott J.
DIABETES, 2013, 62 : A232 - A232
[8] A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
Bergenstal, Richard M.
Rosenstock, Julio
Arakaki, Richard F.
Prince, Melvin J.
Qu, Yongming
Sinha, Vikram P.
Howey, Daniel C.
Jacober, Scott J.
DIABETES CARE, 2012, 35 (11) : 2140 - 2147
[9] PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus
Roder, Michael E.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (04) : 365 - 374
[10] Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM
Jacober, S. J.
Rosenstock, J.
Bergenstal, R. M.
Prince, M. J.
Qu, Y.
Beals, J. M.
DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 351 - 356

← 1 2 3 4 5 →